• 본문 바로가기(Skip Contents)

제넥신 로고

  • Genexine
    • Company
    • Vision
    • History
    • Management
    • Advisor
    • Contact
  • Science
    • Science
    • Publications
    • Intellectual Property
  • R&D
    • CMC Development
    • Non-Clinical Development
    • DNA Vaccine
  • Pipeline
    • Pipeline overview
    • Immuno-oncology
    • Rare Disease
    • Other
  • Partnerships
    • Overview
    • Partnerships
  • Facilities and Operations
    • Pangyo
    • Magok(planned)
  • Investors
    • Monthly News
    • Press Release
    • Notice
    • Event Calendar
    • Awards and Recognitions
  • Careers
    • Overview
    • Benefits
    • Career Opportunities
  • HOME
  • CONTACT
  • KOR
  • Genexine
    • Company
    • Vision
    • History
    • Management
    • Advisor
    • Contact
  • Science
    • Science
    • Publications
    • Intellectual Property
  • R&D
    • CMC Development
    • Non-Clinical Development
    • DNA Vaccine
  • Pipeline
    • Pipeline overview
    • Immuno-oncology
    • Rare Disease
    • Other
  • Partnerships
    • Overview
    • Partnerships
  • Facilities and Operations
    • Pangyo
    • Magok(planned)
  • Investors
    • Monthly News
    • Press Release
    • Notice
    • Event Calendar
    • Awards and Recognitions
  • Careers
    • Overview
    • Benefits
    • Career Opportunities
  • CONTACT
  • KOREAN

Genexine's T cell amplifier GX-I7 Combination with Keytruda for mTNBC Presented at ASCO 2020

Genexine presented clinical trial interim result of GX-I7 combination therapy with Keytruda (MSD, Pembroluzumab) for targeting patients with mTNBC (metastasis Triple Negative Breast Canser) at ASCO 2020.

Genexine's COVID-19 preventative DNA vaccine GX-19 Clinical Trial Ph1/2a approved by MFDS

GX-19 is developed by an international consortium of 6 organizations including Genexine inc., GeNbio, Binex, Postech, KAIST, and IVI

  • Genexine
  • Science
  • R&D
  • Pipeline
  • Partnerships
Copyrightⓒ 2020 Genexine, Inc. All rights reserved.
  • Terms & Conditions
  • CI